Meridian Bioscience, Inc. (VIVO) Misses Q2 EPS by 2c, Reiterates Outlook
Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q2 EPS of $0.18, $0.02 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $41.1 million versus the consensus estimate of $41.2 million.
Meridian Bioscience, Inc. is reiterating its guidance and sees FY2011 EPS of $0.77-$0.82, versus the consensus of $0.78. Meridian Bioscience, Inc. sees FY2011 revenue of $165-$170 million, versus the consensus of $165.55 million.
Meridian Bioscience, Inc. is reiterating its guidance and sees FY2011 EPS of $0.77-$0.82, versus the consensus of $0.78. Meridian Bioscience, Inc. sees FY2011 revenue of $165-$170 million, versus the consensus of $165.55 million.